Dow Jones Business News
ICN's Nebulized Ribavirin Shows Promise Against SARS
Tuesday April 1, 2:24 pm ET
By Steven Vames
NEW YORK -- ICN Pharmaceuticals Inc.'s shares got a little boost Tuesday following press reports that its nebulized version of Ribavirin showed progress in fighting severe acute respiratory syndrome, or SARS, which has affected nearly 2,000 people world-wide.
In afternoon trading on the New York Stock Exchange (News - Websites), shares of ICN traded up 77 cents, or 8.6%, to $9.68.
Earlier, the news pushed shares of ICN's 80%-owned Ribapharm Inc. (NYSE:RNA - News) up nearly 18%, which may have been the result of some confusion by investors. Later, Ribapharm's shares fell nine cents, or 1.7%, to $5.09.
Market Data 
Markets 
AI
